The data strongly suggest that stromal AREG‐mediated PD‐L1 expression in cancer cells represents a major force of resistance to immunosurveillance, a response triggered by the damaged stroma but indeed exploitable to enhance the sensitivity of tumors to immunotherapeutic agents. The gene discussed is CD274; the disease is cancer.